Narcolepsy – Prevalence, Diagnosis and Treatment Options
Event Details
Course introduction: Narcolepsy is a debilitating and incurable neurologic disorder that disrupts the boundaries between sleep and wake states. The prevalence is about 1 in 2000 in the general US
Event Details
Course introduction:
Narcolepsy is a debilitating and incurable neurologic disorder that disrupts the boundaries between sleep and wake states. The prevalence is about 1 in 2000 in the general US population and typically includes patients presenting with Excessive Daytime Sleepiness (EDS) however up to 5% of patients who present with EDS may be underrecognized and underdiagnosed. Idiopathic Hypersomnolence (IH) is a similar condition whose etiology is unknown.
Both conditions are associated with significant morbidity. Their diagnostic evaluation involves a comprehensive office-based evaluation, polysomnographic testing and serum orexin levels, among others.
A variety of treatments are available. Traditionally, stimulants and antidepressants have been utilized for control of daytime sleepiness and cataplexy. More recently, we have seen the introduction of wake promoting agents, hydroxy butyrate preparations, agents that augment histamine neurotransmission, and under development are orexin receptor agonists.
Learning Objectives:
At the conclusion of this eSeminar the participants will be able to:
- Describe the impact of idiopathic hypersomnia and narcolepsy on daytime performance and quality of life among patients and caregivers
- Recognize symptoms and diagnostic criteria of narcolepsy and IH
- Appreciate strengths and limitations of current technology in the diagnostic assessment of narcolepsy and IH
- Integrate the safety, efficacy, and clinical data of novel agents for the treatment of idiopathic hypersomnia and narcolepsy
This course is approved for 1.0 Contact hour by ASET – The Neurodiagnostic Society and 1.0 hour of CSTE from the BRPT – Board of Registered Polysomnographic Technologists.
Speakers for this event
-
Dr. Karl Doghramji
Dr. Karl Doghramji
MD
Dr. Doghramji is a Professor of Psychiatry, Neurology, and Medicine at Jefferson Medical College of Thomas Jefferson University in Philadelphia, Pennsylvania, and Medical Director of the Jefferson Sleep Disorders Center at Thomas Jefferson University Hospital, also in Philadelphia. Dr. Doghramji is also Chair of the Albert M. Biele, MD Memorial Lectureship in Psychiatry in the Department of Psychiatry and Human Behavior at Jefferson Medical College.
As an active member of many professional organizations, Dr. Doghramji has for nearly two decades been the director and lecturer for courses pertaining to sleep disorders at the annual meetings of national organizations including the American Psychiatric Association. He has held numerous committee positions with the American Academy of Sleep Medicine and has served as an examiner for the American Board of Psychiatry and Neurology and the American Board of Sleep Medicine. Dr. Doghramji is a Fellow of the American Academy of Sleep Medicine and a Distinguished Fellow of the American Psychiatric Association and of the Pennsylvania Psychiatric Society.
Dr. Doghramji has authored more than 150 journal publications and book chapters and has edited and written 9 books. He has been the recipient of numerous grants. His published works and research focus on a wide variety of sleep disorders, including excessive daytime somnolence, sleep apnea syndrome, and insomnia, as well as depression and anxiety disorders.MD
Time
(Thursday) 11:00 am - 12:00 pm ET
Location
ONLINE eSeminar
